KR20230005955A - 개 pd-1 결합 폴리펩타이드 및 이의 용도 - Google Patents
개 pd-1 결합 폴리펩타이드 및 이의 용도 Download PDFInfo
- Publication number
- KR20230005955A KR20230005955A KR1020227042086A KR20227042086A KR20230005955A KR 20230005955 A KR20230005955 A KR 20230005955A KR 1020227042086 A KR1020227042086 A KR 1020227042086A KR 20227042086 A KR20227042086 A KR 20227042086A KR 20230005955 A KR20230005955 A KR 20230005955A
- Authority
- KR
- South Korea
- Prior art keywords
- canine
- polypeptide
- gly
- amino acid
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063019817P | 2020-05-04 | 2020-05-04 | |
| US63/019,817 | 2020-05-04 | ||
| PCT/US2021/030476 WO2021225961A1 (en) | 2020-05-04 | 2021-05-03 | Canine pd-1-binding polypeptides and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230005955A true KR20230005955A (ko) | 2023-01-10 |
Family
ID=76076497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227042086A Pending KR20230005955A (ko) | 2020-05-04 | 2021-05-03 | 개 pd-1 결합 폴리펩타이드 및 이의 용도 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230331846A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4146696A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023524995A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230005955A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115776990A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021266688A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022022352A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3177921A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022013840A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021225961A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110982824B (zh) * | 2019-10-09 | 2022-04-15 | 天津大学 | 拮抗pd-1的抗体类似物bp基因及蛋白和应用 |
| US20240254231A1 (en) * | 2023-01-20 | 2024-08-01 | PetMedix Ltd. | Therapeutic antibodies |
| CN117343185B (zh) * | 2023-12-06 | 2024-03-01 | 北京伟杰信生物科技有限公司 | 一种抗犬pd-1抗体及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| DK1678314T3 (da) | 2003-10-22 | 2012-12-03 | Keck Graduate Inst | Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi |
| US9790280B2 (en) * | 2011-10-26 | 2017-10-17 | Elanco Tiergesundheit Ag | Monoclonal canine CD20 antibodies and methods of use |
| AU2014368453B2 (en) * | 2013-12-20 | 2020-04-16 | Intervet International B.V. | Caninized murine anti-canine PD-1 antibodies |
| US10280223B2 (en) * | 2014-07-09 | 2019-05-07 | Nippon Zenyaku Kogyo Co., Ltd. | Anti-canine PD-1 antibody or anti-canine PD-L1 antibody |
| PT3177644T (pt) * | 2014-08-05 | 2021-01-13 | MabQuest SA | Reagentes imunológicos que se ligam a pd-1 |
| ES2853823T3 (es) * | 2014-09-30 | 2021-09-17 | Intervet Int Bv | Anticuerpos de PD-L1 que se unen a PD-L1 canino |
| AU2019356573B2 (en) * | 2018-10-11 | 2025-12-18 | Inhibrx Biosciences, Inc. | PD-1 single domain antibodies and therapeutic compositions thereof |
| CN112920276B (zh) * | 2019-06-03 | 2021-11-12 | 北京希诺谷生物科技有限公司 | 抗犬pd-1抗体及其制备方法 |
-
2021
- 2021-05-03 MX MX2022013840A patent/MX2022013840A/es unknown
- 2021-05-03 AU AU2021266688A patent/AU2021266688A1/en active Pending
- 2021-05-03 US US17/922,569 patent/US20230331846A1/en active Pending
- 2021-05-03 CN CN202180045614.XA patent/CN115776990A/zh active Pending
- 2021-05-03 EP EP21727700.3A patent/EP4146696A1/en active Pending
- 2021-05-03 KR KR1020227042086A patent/KR20230005955A/ko active Pending
- 2021-05-03 CA CA3177921A patent/CA3177921A1/en active Pending
- 2021-05-03 BR BR112022022352A patent/BR112022022352A2/pt unknown
- 2021-05-03 JP JP2022567339A patent/JP2023524995A/ja active Pending
- 2021-05-03 WO PCT/US2021/030476 patent/WO2021225961A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023524995A (ja) | 2023-06-14 |
| AU2021266688A1 (en) | 2022-12-08 |
| MX2022013840A (es) | 2023-02-09 |
| BR112022022352A2 (pt) | 2023-01-10 |
| CA3177921A1 (en) | 2021-11-11 |
| WO2021225961A1 (en) | 2021-11-11 |
| CN115776990A (zh) | 2023-03-10 |
| US20230331846A1 (en) | 2023-10-19 |
| EP4146696A1 (en) | 2023-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI874345B (zh) | 包含經修飾il-2多肽之多肽及其用途 | |
| US12331126B2 (en) | OX40-binding polypeptides and uses thereof | |
| CN114040926A (zh) | 结合cd123的多肽及其用途 | |
| US20230235005A1 (en) | Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof | |
| KR20220004751A (ko) | CLEC12a 결합 폴리펩타이드 및 이의 용도 | |
| JP2024526835A (ja) | Cd8結合ポリペプチド及びその使用 | |
| KR20220004750A (ko) | Cd33 결합 폴리펩타이드 및 이의 용도 | |
| US20250066477A1 (en) | Gamma Delta T-Cell-Binding Polypeptides and Uses Thereof | |
| US20230331846A1 (en) | Canine PD-1-Binding Polypeptides and Uses Thereof | |
| US20250277018A1 (en) | Albumin-Binding Polypeptides and Uses Thereof | |
| KR20230147662A (ko) | Dr5 결합 폴리펩타이드의 제제 | |
| US20250302948A1 (en) | DR5 Agonist and IAP Antagonist Combination Therapy | |
| EA048542B1 (ru) | Связывающие собачий pd-1 полипептиды и их применение | |
| WO2025048860A1 (en) | Ox40 agonist therapy | |
| WO2025048887A1 (en) | Ox40 agonist therapy | |
| US20240254231A1 (en) | Therapeutic antibodies | |
| HK40050757A (en) | Ox40-binding polypeptides and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |